|Bid||33.20 x 1600|
|Ask||34.00 x 500|
|Day's range||35.42 - 37.41|
|52-week range||13.87 - 40.65|
|PE ratio (TTM)||106.49|
|Earnings date||26 Feb 2018 - 2 Mar 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||38.58|
A trio of investors has identified Vertex Pharmaceuticals, Proofpoint, and Baozun as companies capable of delivering better returns to shareholders from here than the e-commerce giant.
When the market is attractive you want to be 100% invested. But when risks are too high to stomach, a less aggressive strategy makes sense. Aalok Devkota has managed his market exposure so well that he beat all U.S. equity mutual fund managers for the past 3 years. He is turning aggressive now.
Major technology trends will have knock-on benefits in the Chinese economy, a hedge fund executive said on Monday.
Jim Cramer speeds through his take on callers' favorite stocks, including one Chinese company he recently discovered.